Aldeyra Therapeutics (NASDAQ:ALDX) Director Richard Douglas Acquires 200,000 Shares of Company Stock

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX – Get Free Report) Director Richard Douglas purchased 200,000 shares of the stock in a transaction on Wednesday, November 11th. The shares were purchased at an average cost of $0.64 per share, for a total transaction of $128,000.00. Following the acquisition, the director directly owned 395,000 shares of the company’s stock, valued at approximately $252,800. This represents a 102.56% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Aldeyra Therapeutics Stock Performance

Shares of NASDAQ ALDX traded up $0.01 during midday trading on Friday, reaching $0.64. The stock had a trading volume of 734,135 shares, compared to its average volume of 867,410. The company has a market capitalization of $38.86 million, a price-to-earnings ratio of -2.01 and a beta of 1.32. Aldeyra Therapeutics, Inc. has a 12-month low of $0.53 and a 12-month high of $5.93. The stock has a 50-day moving average of $0.97 and a 200-day moving average of $2.09.

Aldeyra Therapeutics (NASDAQ:ALDX – Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The biotechnology company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.05. As a group, analysts forecast that Aldeyra Therapeutics, Inc. will post -0.27 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on ALDX shares. HC Wainwright reaffirmed a “neutral” rating and set a $2.00 price target on shares of Aldeyra Therapeutics in a research note on Wednesday, September 30th. Wall Street Zen cut shares of Aldeyra Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Weiss Ratings downgraded shares of Aldeyra Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, September 14th. Finally, BTIG Research restated a “buy” rating on shares of Aldeyra Therapeutics in a report on Tuesday, September 29th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $2.00.

Get Our Latest Stock Analysis on Aldeyra Therapeutics

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Squarepoint Ops LLC purchased a new position in shares of Aldeyra Therapeutics during the 2nd quarter worth about $200,000. Two Sigma Securities LLC purchased a new stake in Aldeyra Therapeutics in the 2nd quarter worth about $70,000. Palo Alto Investors LP purchased a new stake in Aldeyra Therapeutics in the 2nd quarter worth about $331,660. Bank of America Corp DE bought a new stake in Aldeyra Therapeutics in the second quarter worth about $72,000. Finally, Man Group plc bought a new stake in Aldeyra Therapeutics in the second quarter worth about $325,000. Institutional investors own 59.71% of the company’s stock.

About Aldeyra Therapeutics

(Get Free Report)

Aldeyra Therapeutics, Inc. is a biotechnology company focused on developing treatments for immune-mediated diseases, including conditions affecting the eye. The company’s research centers on reactive aldehyde species (RASP), which it aims to inhibit to address inflammation and related disease processes. Aldeyra’s investigational medicines include reproxalap, a small-molecule RASP inhibitor studied for ocular conditions such as dry eye disease and allergic conjunctivitis. Its pipeline has also included candidates intended to treat systemic immune-mediated conditions.

Featured Articles

Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.